56822-33-4

Basic information

• Product Name: 3',5'-DI-O-MESYLTHYMIDINE
• Synonyms: 3',5'-DI-O-MESYLTHYMIDINE;3',5'-DI-O-METHYLSULFONYL THYMIDINE
• CAS NO: 56822-33-4
• Molecular Formula: C₁₂H₁₈N₂O₉S₂
• Molecular Weight: 398.41
• Product Categories: Miscellaneous Biochemicals;Stavudine
• Mol File: 56822-33-4.mol
• Article Data: 21

Chemical Properties

• Appearance: /
• Density: 1.59 g/cm³
• CAS DataBase Reference: 3',5'-DI-O-MESYLTHYMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3',5'-DI-O-MESYLTHYMIDINE(56822-33-4)
• EPA Substance Registry System: 3',5'-DI-O-MESYLTHYMIDINE(56822-33-4)

Safety Data

• Hazardous Substances Data: 56822-33-4(Hazardous Substances Data)

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 50-89-5 thymidine 
• 75-75-2 methanesulfonic acid 
• 15981-86-9 1-(2,3'-Anhydro-5'-O-methylsulfonyl-2-deoxy-β-D-threo-pentofuranosyl)thymine 

Downstream Products

• 556826-39-2 5'-monomethoxytritylamino-3'-(N'-9-fluorenylmethoxycarbonylthiouria)-2',3',5'-trideoxythymidine 
• 209255-51-6 5'-monomethoxytritylamino-3'-amino-2',3',5'-trideoxythymidine 
• 29108-89-2 3',5'-dideoxythymidine 
• 25526-93-6 alovudine 
• 134767-53-6 Octanoic acid (2S,5R)-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2,5-dihydro-furan-2-ylmethyl ester 
• 183428-15-1 1-[(2R,4S,5R)-4-(4-Methoxy-benzylsulfanyl)-5-(4-methoxy-benzylsulfanylmethyl)-tetrahydro-furan-2-yl]-5-methyl-1H-pyrimidine-2,4-dione 
• 3416-05-5 3'-Deoxythymidine 
• 3056-17-5 stavudin 
• 928138-25-4 C₁₇H₁₅N₃O₈ 
• 34308-10-6 3'-O-mesylthymidine 
• 7481-90-5 3',4'-anhydrothymidine 
• 15981-86-9 5'-O-mesyl-2,3'-anhydro-thymidine 
• 140175-70-8 1,2,5,6-tetradeoxy-1-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-β-D-erythro-hexofuranurono-6,3-sultone 
• 5983-11-9 2-methyl-5-(thymin-1-yl)furan 

Relevant articles and documents

Synthesis of 5'-ethynyl-2'-deoxynucleoside analogues as building block for antisense oligonucleotide

New nucleosides and nucleoside analogue dimers were prepared using 5'- ethynyl-2'-deoxynucleoside as starting material.

Deoxynucleic Guanidines (DNG)- Modified Oligonucleotides and Methods of Synthesizing Deoxynucleic Guanidine Strands

Disclosed herein are spherical nucleic acids (SNAs) comprising oligonucleotides comprising one or more modified oligonucleotides, and methods of use thereof. Also disclosed are methods of synthesizing modified oligonucleotides for use in therapeutics, inc

Mitochondrial mode of action of a thymidine-based cisplatin analogue breaks resistance in cancer cells

Cisplatin analogue complexes with platinum(II) and palladium(II) starting from 3′,5′-diamino-3′,5′-dideoxy-thymidines were synthesized, both with the D-erythro- and D-threo configurations. Complexes of the general formula [MCl2L] were obtained and characterized. NMR spectroscopic measurements and single crystal X-ray structure analysis showed that the metal centers are coordinated to the ligands by the amino groups in 3′- and 5′-positions and not through the thymine moiety. All ligands and complexes showed no significant in vitro activities except thymiplatin (cis-dichloro(3′,5′-diamino-3′,5′-dideoxy-D-threo- thymidine)platinum(II)). Detailed in vitro studies on the apoptosis pathway in lymphoma (BJAB), leukemia (NALM-6), and melanoma cells (Mel-HO) as well as on transfected or resistant cell lines were carried out. Thymiplatin significantly induced an apoptotic response, which was found to be associated with the loss of mitochondrial membrane potential and with caspase activation. The activity was shown to be independent of Fas-associated protein with death domain (FADD), but dependent on Bcl-2 expression. As a consequence, for thymiplatin a mitochondrial mode of action could be assigned. Moreover, the compound showed activity in cells resistant to common drugs, such as daunorubicin and vincristin, and showed synergistic effects with doxorubicin, vincristin, cytarabin, and daunorubicin. Prove your metal: Cisplatin analogues with platinum(II) and palladium(II) complexes based on 3′,5′-diamino thymidines were synthesized (see figure for an example) and one was found to induce apoptosis mediated by caspase-9 and -3 processing. Thymiplatin was proven to be active on cisplatin, vincristin and daunorubicin resistant leukemia cells, and was synergistic with cytarabin, vincristin, daunorubicin, and doxorubicin in lymphoma cells. Copyright